
Basel, Switzerland – 18 Dec, 2024, Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer effective February 1, 2025. Dr. Sachse brings more than 25 years of experience in the biopharma industry as a physician and scientist and was most recently the Chief Medical Officer of SOTIO Biotech. Dr. Sachse will succeed Eduard Gasal, M.D. who will be leaving Anaveon to explore a new opportunity.
”We are delighted to welcome Richard to our team as Chief Medical Officer. He brings a wealth of experience across all aspects of clinical development, clinical operations and medical affairs, and his experience will be invaluable as we advance our lead program ANV600, as well as develop our broader pipeline. I would like to thank Ed for his exceptional contributions to Anaveon over the past two years, including the execution of Anaveon’s clinical development pipeline, and particularly for bringing ANV600 successfully to clinic with first patients being treated in June of this year. We wish him well in his future endeavours.
Andreas KatopodisChief Executive Officer of Anaveon